|
US4756911A
(en)
|
1986-04-16 |
1988-07-12 |
E. R. Squibb & Sons, Inc. |
Controlled release formulation
|
|
US5378475A
(en)
|
1991-02-21 |
1995-01-03 |
University Of Kentucky Research Foundation |
Sustained release drug delivery devices
|
|
WO1994012880A2
(en)
|
1992-11-25 |
1994-06-09 |
La Jolla Cancer Research Foundation |
Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression
|
|
US5466861A
(en)
|
1992-11-25 |
1995-11-14 |
Sri International |
Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
|
|
EP0638071B1
(en)
|
1992-12-28 |
1997-04-09 |
Eisai Co., Ltd. |
Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
|
|
US5455265A
(en)
|
1993-02-11 |
1995-10-03 |
Allergan, Inc. |
Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
|
|
US5869079A
(en)
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
|
US5675033A
(en)
|
1995-06-06 |
1997-10-07 |
Allergan |
2,4-pentadienoic acid derivatives having retinoid-like biological activity
|
|
US5917082A
(en)
|
1995-06-06 |
1999-06-29 |
Allergan Sales, Inc. |
2,4-pentadienoic acid derivatives having retinoid-like biological activity
|
|
JP3964478B2
(ja)
|
1995-06-30 |
2007-08-22 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
|
|
US6942980B1
(en)
|
1995-09-01 |
2005-09-13 |
Allergan, Inc. |
Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
|
|
US5952345A
(en)
|
1995-09-01 |
1999-09-14 |
Allergan Sales, Inc. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
|
US6218128B1
(en)
|
1997-09-12 |
2001-04-17 |
Allergan Sales, Inc. |
Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
|
|
US5958954A
(en)
|
1995-09-01 |
1999-09-28 |
Allergan Sales, Inc. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
|
US6008204A
(en)
|
1995-09-01 |
1999-12-28 |
Allergan Sales, Inc. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
|
US5776699A
(en)
|
1995-09-01 |
1998-07-07 |
Allergan, Inc. |
Method of identifying negative hormone and/or antagonist activities
|
|
US5675024A
(en)
|
1995-11-22 |
1997-10-07 |
Allergan |
Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
|
|
US5965606A
(en)
|
1995-12-29 |
1999-10-12 |
Allergan Sales, Inc. |
Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
|
|
US5877207A
(en)
|
1996-03-11 |
1999-03-02 |
Allergan Sales, Inc. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
|
US20030219832A1
(en)
|
1996-03-11 |
2003-11-27 |
Klein Elliott S. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
|
US6441025B2
(en)
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
|
US6555690B2
(en)
|
1996-06-21 |
2003-04-29 |
Allergan, Inc. |
Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
|
|
US5763635A
(en)
|
1996-06-21 |
1998-06-09 |
Allergan |
Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
|
|
US5773594A
(en)
|
1996-06-21 |
1998-06-30 |
Allergan |
Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
|
|
US5739338A
(en)
|
1996-11-05 |
1998-04-14 |
Allergan |
N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
|
|
DE69726182T2
(de)
|
1996-12-11 |
2004-08-12 |
Dana-Farber Cancer Institute, Inc., Boston |
Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
|
|
US5728846A
(en)
|
1996-12-12 |
1998-03-17 |
Allergan |
Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
|
|
US6037488A
(en)
|
1997-04-19 |
2000-03-14 |
Allergan Sales, Inc. |
Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
|
|
US5919970A
(en)
|
1997-04-24 |
1999-07-06 |
Allergan Sales, Inc. |
Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
|
|
US6670398B2
(en)
|
1997-05-14 |
2003-12-30 |
Atherogenics, Inc. |
Compounds and methods for treating transplant rejection
|
|
US6063768A
(en)
|
1997-09-04 |
2000-05-16 |
First; Eric R. |
Application of botulinum toxin to the management of neurogenic inflammatory disorders
|
|
AU3595099A
(en)
|
1998-05-11 |
1999-11-29 |
Novo Nordisk A/S |
New compounds, their preparation and use
|
|
CA2334545A1
(en)
|
1998-06-12 |
1999-12-16 |
Ligand Pharmaceuticals Incorporated |
Treatment of anti-estrogen resistant breast cancer using rxr modulators
|
|
US6048873A
(en)
|
1998-10-01 |
2000-04-11 |
Allergan Sales, Inc. |
Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
|
|
US6403638B1
(en)
|
1998-10-01 |
2002-06-11 |
Allergan Sales, Inc. |
2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
|
|
US6147224A
(en)
|
1998-10-01 |
2000-11-14 |
Allergan Sales, Inc. |
2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
|
|
US6521641B1
(en)
|
1998-10-08 |
2003-02-18 |
Allergan, Inc. |
Male anti-fertility agents
|
|
US6776984B1
(en)
|
1999-08-20 |
2004-08-17 |
George R. Schwartz |
Induced regeneration and repair of damaged neurons and nerve axon myelin
|
|
US6043381A
(en)
|
1999-05-07 |
2000-03-28 |
Allergan Sales, Inc. |
Process for preparing substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo[1,2-g]-1,2-dihydroquinoline derivatives
|
|
AU6228000A
(en)
|
1999-07-23 |
2001-02-13 |
Allergan Sales, Inc. |
The use of retinoid receptor antagonists in the treatment of prostate carcinoma
|
|
US6187750B1
(en)
|
1999-08-25 |
2001-02-13 |
Everyoung Technologies, Inc. |
Method of hormone treatment for patients with symptoms consistent with multiple sclerosis
|
|
US6593493B1
(en)
|
1999-09-14 |
2003-07-15 |
Ligand Pharmaceuticals, Inc. |
RXR modulators with improved pharmacologic profile
|
|
US6313168B1
(en)
|
1999-12-15 |
2001-11-06 |
Allergan Sales, Inc. |
Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
|
|
TWI281911B
(en)
|
2000-04-04 |
2007-06-01 |
Allergan Inc |
Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents
|
|
US20030077664A1
(en)
|
2001-04-18 |
2003-04-24 |
Yi Zhao |
Methods of screening for compounds that modulate hormone receptor activity
|
|
US20020193403A1
(en)
|
2001-05-03 |
2002-12-19 |
Allergan Sales, Inc. |
Methods of treating hyperlipidemia
|
|
AU2002315306B2
(en)
|
2001-05-08 |
2007-05-17 |
Merck Patent Gmbh |
Combination therapy using anti-EGFR antibodies and anti-hormonal agents
|
|
GB0111314D0
(en)
*
|
2001-05-09 |
2001-07-04 |
Karobio Ab |
Dermatological formulations
|
|
WO2003027090A2
(en)
|
2001-09-25 |
2003-04-03 |
Smithkline Beecham Corporation |
Bicyclic heterocycles as rxr ligands
|
|
US6645526B2
(en)
|
2001-11-13 |
2003-11-11 |
Mylan Pharmaceuticals, Inc. |
Storage stable thyroxine active drug formulations and methods for their production
|
|
IL152904A0
(en)
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
|
JP2005520511A
(ja)
|
2002-03-18 |
2005-07-14 |
ガミダ セル リミテッド |
エクスビボ拡大培養された幹細胞における分化を誘導する方法
|
|
US6720423B2
(en)
|
2002-04-30 |
2004-04-13 |
Allergan, Inc. |
Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
|
|
BR0309896A
(pt)
|
2002-06-04 |
2005-03-22 |
Galderma Res & Dev |
Compostos, uso em um composto, composição farmacêutica, composição cosmética, uso cosmético de uma composição
|
|
US20040005304A1
(en)
|
2002-07-08 |
2004-01-08 |
Mak Wood, Inc. |
Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
|
|
JP4275365B2
(ja)
|
2002-08-06 |
2009-06-10 |
三菱電機株式会社 |
複合形ガス絶縁開閉装置
|
|
US7105566B2
(en)
|
2002-10-22 |
2006-09-12 |
Allergan, Inc. |
Methods of treatment during vascular procedures
|
|
EP1565433B1
(en)
|
2002-11-18 |
2007-03-14 |
Galderma Research & Development, S.N.C. |
Novel ligands that are antagonists of rar receptors, process for preparing them and use thereof in human medicine and in cosmetics
|
|
US7019034B2
(en)
|
2003-01-28 |
2006-03-28 |
Allergan, Inc. |
Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
|
|
US6936636B2
(en)
|
2003-06-26 |
2005-08-30 |
Allergan, Inc. |
5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
|
|
AU2004263156B2
(en)
*
|
2003-08-07 |
2009-02-26 |
Allergan, Inc. |
Method for treating cachexia with retinoid ligands
|
|
AU2004273986B2
(en)
|
2003-09-15 |
2010-04-22 |
Nanopharmaceuticals Llc |
Thyroid hormone analogs and methods of use in angiogenesis
|
|
WO2005046726A2
(en)
|
2003-11-12 |
2005-05-26 |
Allergan, Inc. |
Combinations for inhibiting cell growth which contains an inhibitor of human ck1 alpha activity and a rxr agonist
|
|
EP1706095B1
(en)
|
2004-01-20 |
2008-12-24 |
Allergan, Inc. |
Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
|
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
|
WO2006030442A2
(en)
|
2004-09-16 |
2006-03-23 |
Gamida-Cell Ltd. |
Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
|
|
US8105611B2
(en)
|
2005-06-17 |
2012-01-31 |
Allergan, Inc. |
Treatment of autoimmune disorder with a neurotoxin
|
|
WO2007022408A2
(en)
*
|
2005-08-18 |
2007-02-22 |
Merck & Co., Inc. |
Combination methods of saha and targretin for treating cancer
|
|
WO2007041077A2
(en)
|
2005-09-30 |
2007-04-12 |
Janssen Pharmaceutica N.V. |
Heterocyclic amide derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
|
|
CN101316821A
(zh)
*
|
2005-09-30 |
2008-12-03 |
詹森药业有限公司 |
作为rxr激动剂用于治疗异常脂肪血症、高胆固醇血症和糖尿病的二氢-[1h]-喹啉-2-酮衍生物
|
|
CA2624345A1
(en)
|
2005-09-30 |
2007-04-12 |
Janssen Pharmaceutica N.V. |
1,2,3,5-tetrahydro-cyclopental[c]quinolin-4-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
|
|
LT1937244T
(lt)
|
2005-09-30 |
2018-11-12 |
Io Therapeutics, Llc |
Vėžio gydymas specifiniais rxr agonistais
|
|
US20070185055A1
(en)
|
2006-02-06 |
2007-08-09 |
Guang Liang Jiang |
Method for treating cachexia with retinoid ligands
|
|
CN1806798A
(zh)
*
|
2006-02-23 |
2006-07-26 |
北京阜康仁生物制药科技有限公司 |
一种以贝沙罗汀为活性成分的药用组合物及其制备方法、用途
|
|
KR101530050B1
(ko)
|
2007-03-02 |
2015-06-22 |
주식회사 노브메타파마 |
알츠하이머 질환 및 치매를 치료하기 위한 조성물 및 방법
|
|
JP2010531138A
(ja)
|
2007-06-13 |
2010-09-24 |
ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー |
制御性ｔ細胞ならびに同製造および使用方法
|
|
US20090209601A1
(en)
|
2008-02-15 |
2009-08-20 |
Wyeth |
Use of rxr agonists for the treatment of osteoarthritis
|
|
ES2332169B1
(es)
|
2008-07-24 |
2010-10-25 |
Universidad Del Pais Vasco |
Empleo de microparticulas que comprenden celulas modificadas geneticamente en el tratamiento de enfermedades neurodegenerativas.
|
|
ES2632213T3
(es)
|
2008-10-08 |
2017-09-11 |
Cambridge Enterprise Limited |
Métodos y composiciones para diagnosticar y tratar una enfermedad autoinmunitaria que es secundaria con respecto a la esclerosis múltiple
|
|
JP5542059B2
(ja)
|
2008-10-09 |
2014-07-09 |
国立大学法人 岡山大学 |
Ｒｘｒ作動性物質を有効成分とする抗アレルギー剤
|
|
US8420077B2
(en)
|
2009-04-20 |
2013-04-16 |
Allergan, Inc. |
Silk fibroin hydrogels and uses thereof
|
|
CA2761298A1
(en)
|
2009-05-15 |
2010-11-18 |
The University Of Kentucky Research Foundation |
Treatment of mci and alzheimer's disease
|
|
US20100298434A1
(en)
|
2009-05-21 |
2010-11-25 |
Claude Rouillard |
Neuroprotection and prevention of dopaminergic cell death by targeting nur77 translocation
|
|
JP2010280585A
(ja)
|
2009-06-02 |
2010-12-16 |
Okayama Univ |
Ｒｘｒ作動性物質を有効成分とする鎮痛剤
|
|
WO2011006157A2
(en)
|
2009-07-10 |
2011-01-13 |
Case Western Reserve University |
Rxr agonist compounds and methods
|
|
CA2790318A1
(en)
|
2010-02-19 |
2011-08-25 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acti Ng For And On Behalf Of Arizona State University |
Novel bexarotene analogs
|
|
EP2685972A4
(en)
|
2011-03-14 |
2014-08-13 |
Io Therapeutics Inc |
TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH RAR ALPHA SELECTIVE AGONISTS
|
|
EP2556827A1
(en)
*
|
2011-08-11 |
2013-02-13 |
Acadia Pharmaceuticals Inc. |
Treatment of neurodegenerative diseases
|
|
WO2013056232A2
(en)
|
2011-10-13 |
2013-04-18 |
Case Western Reserve University |
Rxr agonists compounds and methods
|
|
US10653650B2
(en)
|
2011-12-13 |
2020-05-19 |
Io Therapeutics, Inc. |
Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
|
|
CN110151745A
(zh)
|
2011-12-13 |
2019-08-23 |
Io治疗公司 |
使用rxr激动剂的自身免疫紊乱的治疗
|
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
|
US20160263189A1
(en)
|
2013-10-23 |
2016-09-15 |
Acadia Pharmaceuticals Inc. |
Treatment of a neurodegenerative disease or disorder
|
|
JP2016537414A
(ja)
|
2013-10-29 |
2016-12-01 |
ベスティオン、インク． |
心臓神経堤細胞、及びその使用方法
|
|
WO2016144976A1
(en)
|
2015-03-09 |
2016-09-15 |
Kings College London |
Combination therapy with rar alpha agonists for enhancing th1 response
|
|
WO2017075612A1
(en)
|
2015-10-31 |
2017-05-04 |
Io Therapeutics, Inc. |
Treatment of cancer with combinations of rxr agonists and thyroid hormones
|
|
US20180318241A1
(en)
|
2015-10-31 |
2018-11-08 |
Io Therapeutics, Inc. |
Treatment of nervous system disorders using thyroid hormone neutral doses of rxr agonists
|
|
KR102149321B1
(ko)
|
2015-10-31 |
2020-08-28 |
아이오 테라퓨틱스, 인크. |
Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
|
|
NZ745704A
(en)
|
2016-03-10 |
2019-04-26 |
Io Therapeutics Inc |
Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
|
|
KR102549273B1
(ko)
|
2016-03-10 |
2023-06-28 |
아이오 테라퓨틱스, 인크. |
Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
|
|
CN106983738B
(zh)
*
|
2017-04-13 |
2020-03-10 |
深圳市润佳通科技有限公司 |
甲状腺激素及其药学上可接受的盐或前药在制备治疗和/或预防皮肤疾病的药物中的应用
|
|
CA3073953A1
(en)
|
2017-08-31 |
2019-03-07 |
Io Therapeutics, Inc. |
Rar selective agonists in combination with immune modulators for cancer immunotherapy
|
|
EP3684348A4
(en)
|
2017-09-20 |
2021-08-18 |
IO Therapeutics, Inc. |
TREATMENT OF DISEASES WITH ETERS FROM SELECTIVE RXR AGONISTS
|
|
KR102715396B1
(ko)
|
2017-11-17 |
2024-10-08 |
아이오 테라퓨틱스, 인크. |
레티노이드 x 수용체 특이적 레티노이드의 제조를 위한 화합물 및 합성 방법
|
|
US10966950B2
(en)
|
2019-06-11 |
2021-04-06 |
Io Therapeutics, Inc. |
Use of an RXR agonist in treating HER2+ cancers
|